MD_ID,PATIENT_ID,COUNTRY,Line of therapy,Year of birth,Age at diagnosis,Gender,Race,Adequate caretaker support,Travel time to your office < 30 min,Patient's level of involvement in GBM,Patient's treatment goals,Primary insurance,Comorbidity: Renal impairment,Comorbidity: Anemia,Comorbidity: COPD/Pulmonary,Comorbidity: Diabetes,Comorbidity: CHF (Cong. Heart Failure),Comorbidity: Neuropathies,Comorbidity: Other Neurological,Comorbidity: Hepatic insufficiency,Comorbidity: Other cytopenia,Comorbidity: Autoimmune disorder,Comorbidity: Hypertension,Comorbidity: Other Cardiovascular,Comorbidity: Alzheimer's,Comorbidity: Other cancer (besides GBM),Comorbidity: Other (specify),Comorbidity: Other (specify),Comorbidity: None,ECOG At 1st Line,ECOG At 2nd Line,MGMT methylated,EGFR mutated,TP53 mutated,IDH1/IDH2 mutated,PD-L1 overexpressed,% of tumor mass surgically resected,Regimen in 1st Line,Regimen in 1st Line (Other),Regimen in 2nd Line,Regimen in 2nd Line (Other)
10487,104871,US,1L,1954,58,Male,Black/African,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,9,9,9,9,9,10,Avastin mono, ,999, 
10487,104872,US,1L,1947,66,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,PPO,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,0,2,9,9,9,9,9,9,999,Avastin + Lomustine, ,999, 
10487,104873,US,2L,1957,56,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,9,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,2,9,9,9,9,9,999,Avastin + Irinotecan, ,Avastin mono, 
10487,104874,US,2L,1955,58,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,9,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,2,9,9,9,9,9,999,Avastin + Irinotecan, ,TMZ mono, 
10487,104875,US,2L,1946,67,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,2,9,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
10488,104881,US,1L,1948,67,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,0,9,9,9,90,Avastin + TMZ, ,999, 
10488,104882,US,1L,1945,70,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,0,1,9,9,0,90,TMZ mono, ,999, 
10488,104883,US,2L,1948,66,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,1,0,9,9,0,90,TMZ mono, ,Avastin + TMZ, 
10488,104884,US,2L,1940,74,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,9,9,9,9,90,TMZ mono, ,Avastin + TMZ, 
10488,104885,US,2L,1945,69,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,1,9,9,0,95,Lomustine mono, ,Avastin + TMZ, 
10489,104891,US,1L,1965,50,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,80,TMZ mono, ,999, 
10489,104892,US,1L,1958,57,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,9,9,9,9,9,9,75,TMZ mono, ,999, 
10489,104893,US,2L,1970,44,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,75,TMZ mono, ,Avastin mono, 
10489,104894,US,2L,1967,47,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,75,TMZ mono, ,Avastin mono, 
10489,104895,US,2L,1950,64,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,80,TMZ mono, ,Avastin mono, 
10490,104901,US,1L,1954,61,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,999,Avastin mono, ,999, 
10490,104902,US,1L,1963,52,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,999,Avastin mono, ,999, 
10490,104903,US,2L,1959,56,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10490,104904,US,2L,1950,65,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10490,104905,US,2L,1965,50,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10502,105021,US,1L,1945,69,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,1,9,9,9,999,Lomustine mono, ,999, 
10502,105022,US,1L,1966,47,Male,White/Caucasian,1,1,Passive / not interested / unengaged,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,999,TMZ mono, ,999, 
10502,105023,US,2L,1955,57,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0, ,0,1,2,0,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
10502,105024,US,2L,1945,64,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,0,1,9,9,9,9,999,Avastin + Irinotecan, ,Avastin mono, 
10502,105025,US,2L,1965,44,Male,Black/African,0,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0, ,0,1,1,0,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
10517,105171,US,1L,1980,35,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,90,TMZ mono, ,999, 
10517,105172,US,1L,1970,45,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,disc disease,0,1,9,9,9,9,9,9,90,TMZ mono, ,999, 
10517,105173,US,2L,1945,70,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,2,2,1,9,9,9,9,70,TMZ mono, ,TMZ mono, 
10517,105174,US,2L,1950,64,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0, ,0,1,1,1,9,9,9,9,90,TMZ mono, ,TMZ mono, 
10517,105175,US,2L,1960,54,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"elevated cholesterol, Herniated disc s/p surgery",0,1,2,9,9,9,9,9,90,TMZ mono, ,Avastin mono, 
10521,105211,US,1L,1955,60,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,0,9,0,0,999,Avastin + TMZ, ,999, 
10521,105212,US,1L,1948,66,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,0,0,0,1,1,70,Avastin + TMZ, ,999, 
10521,105213,US,2L,1944,70,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,3,0,0,9,9,9,80,Avastin + Irinotecan, ,Lomustine mono, 
10521,105214,US,2L,1960,54,Male,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Survival,PPO,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0, ,0,2,3,0,1,0,0,0,40,Avastin + Irinotecan, ,Lomustine mono, 
10521,105215,US,2L,1952,62,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0, ,0,2,4,0,0,1,1,1,80,Avastin + TMZ, ,TMZ mono, 
10539,105391,US,1L,1954,61,Male,Spanish/Hispanic/Latino,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,9,9,9,9,50,TMZ mono, ,999, 
10539,105392,US,1L,1972,43,Female,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,9,9,1,1,80,Lomustine mono, ,999, 
10539,105393,US,2L,1945,70,Female,Spanish/Hispanic/Latino,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,2,0,9,9,9,9,60,Lomustine mono, ,Avastin + Irinotecan, 
10539,105394,US,2L,1960,55,Male,Asian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,1,9,9,9,9,90,TMZ mono, ,Avastin + Irinotecan, 
10539,105395,US,2L,1980,35,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,9,9,9,9,60,Lomustine mono, ,Avastin + Irinotecan, 
10543,105431,US,1L,1954,61,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,0,0,0,999,Avastin mono, ,999, 
10543,105432,US,1L,1948,67,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,0,0,0,999,Avastin mono, ,999, 
10543,105433,US,2L,1944,69,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,0,0,0,0,999,TMZ mono, ,Avastin + TMZ, 
10543,105434,US,2L,1957,56,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,0,0,0,0,999,TMZ mono, ,Avastin + TMZ, 
10543,105435,US,2L,1950,63,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,0,0,0,0,999,TMZ mono, ,Avastin + TMZ, 
10554,105541,US,1L,1935,84,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,30,TMZ mono, ,999, 
10554,105542,US,1L,1940,79,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,40,TMZ mono, ,999, 
10554,105543,US,2L,1950,69,Male,Asian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,90,TMZ mono, ,TMZ mono, 
10554,105544,US,2L,1940,79,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,80,TMZ mono, ,TMZ mono, 
10554,105545,US,2L,1949,70,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,95,TMZ mono, ,TMZ mono, 
10556,105561,US,1L,1950,65,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,0,1,0,0,0,70,Avastin + TMZ, ,999, 
10556,105562,US,1L,1963,52,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,0,0,0,85,TMZ mono, ,999, 
10556,105563,US,2L,1956,59,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,1,0,0,0,80,TMZ mono, ,Avastin + TMZ, 
10556,105564,US,2L,1965,50,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,0,0,0,80,Lomustine mono, ,Avastin + TMZ, 
10556,105565,US,2L,1945,70,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,0,0,0,0,86,Lomustine mono, ,Avastin + TMZ, 
10569,105691,US,1L,1944,71,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,999,Avastin mono, ,999, 
10569,105692,US,1L,1948,67,Male,Black/African,0,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,999,Avastin mono, ,999, 
10569,105693,US,2L,1938,77,Female,Asian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,0,9,9,9,9,999,Avastin mono, ,Avastin + Irinotecan, 
10569,105694,US,2L,1932,83,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,9,9,9,9,999,Avastin mono, ,Avastin + Irinotecan, 
10569,105695,US,2L,1939,75,Male,Asian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,1,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10574,105741,US,1L,1956,59,Male,White/Caucasian,1,9,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,90,TMZ mono, ,999, 
10574,105742,US,1L,1958,57,Male,White/Caucasian,1,9,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,9,9,9,9,95,TMZ mono, ,999, 
10574,105743,US,2L,1963,52,Female,Black/African,1,9,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,1,9,9,9,9,90,TMZ mono, ,Avastin mono, 
10574,105744,US,2L,1963,51,Male,White/Caucasian,1,9,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,9,9,9,9,85,TMZ mono, ,Avastin mono, 
10574,105745,US,2L,1957,57,Male,White/Caucasian,1,9,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,95,TMZ mono, ,Avastin mono, 
10582,105821,US,1L,1965,50,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,9,9,9,9,90,TMZ mono, ,999, 
10582,105822,US,1L,1955,60,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,9,9,9,9,80,TMZ mono, ,999, 
10582,105823,US,2L,1966,49,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,9,9,9,9,85,TMZ mono, ,Avastin mono, 
10582,105824,US,2L,1965,50,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,9,9,9,9,999,Avastin mono, ,Avastin + Irinotecan, 
10582,105825,US,2L,1955,60,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10584,105841,US,1L,1955,64,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0, ,1,4,9,9,9,9,9,9,999,TMZ mono, ,999, 
10584,105842,US,1L,1983,36,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0, ,1,4,9,9,9,9,9,9,100,TMZ mono, ,999, 
10584,105843,US,2L,1982,37,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
10584,105844,US,2L,1950,69,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
10584,105845,US,2L,1946,73,Female,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0, ,1,4,0,9,9,9,9,9,90,TMZ mono, ,TMZ mono, 
10588,105881,US,1L,1943,72,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0, ,0,2,9,1,9,9,0,1,40,TMZ mono, ,999, 
10588,105882,US,1L,1944,71,Female,Black/African,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,2,9,1,1,0,0,0,45,TMZ mono, ,999, 
10588,105883,US,2L,1938,77,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,4,1,1,0,1,1,30,TMZ mono, ,Avastin + TMZ, 
10588,105884,US,2L,1946,69,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,VA/Other government,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,0,1,1,1,1,20,TMZ mono, ,Avastin + TMZ, 
10588,105885,US,2L,1950,65,Male,Spanish/Hispanic/Latino,0,0,Passive / not interested / unengaged,More focused on Quality of Life,VA/Other government,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0, ,0,3,3,0,0,0,0,0,40,Lomustine mono, ,Avastin + Lomustine, 
10589,105891,US,1L,1952,63,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicaid,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0, ,0,1,9,0,9,9,9,9,75,Avastin + TMZ, ,999, 
10589,105892,US,1L,1951,64,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,9,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0, ,0,1,9,0,0,0,0,0,80,Lomustine mono, ,999, 
10589,105893,US,2L,1955,60,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0, ,0,2,2,0,9,0,1,1,70,TMZ mono, ,Avastin + TMZ, 
10589,105894,US,2L,1953,62,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,Medicaid,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,2,2,0,1,0,0,1,60,Lomustine mono, ,Avastin + TMZ, 
10589,105895,US,2L,1957,58,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0, ,0,2,2,0,0,9,1,1,69,TMZ mono, ,Avastin + TMZ, 
10590,105901,US,1L,1935,80,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,9,9,9,9,999,Avastin mono, ,999, 
10590,105902,US,1L,1932,83,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,9,0,9,9,9,9,999,Avastin mono, ,999, 
10590,105903,US,2L,1938,77,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,1,0,9,9,9,9,999,Lomustine mono, ,Avastin mono, 
10590,105904,US,2L,1941,73,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,1,0,9,9,9,9,999,Lomustine mono, ,Avastin mono, 
10590,105905,US,2L,1944,70,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,9,9,9,9,999,Avastin mono, ,Avastin + Lomustine, 
10591,105911,US,1L,1969,45,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,9,9,9,9,90,Avastin + Irinotecan, ,999, 
10591,105912,US,1L,1979,36,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,9,9,9,9,999,Avastin + TMZ, ,999, 
10591,105913,US,2L,1965,48,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,0,9,9,9,9,70,Avastin + TMZ, ,Avastin + Lomustine, 
10591,105914,US,2L,1948,66,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Survival,Medicare,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,9,9,9,9,50,Avastin + TMZ, ,Avastin + Irinotecan, 
10591,105915,US,2L,1964,50,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,9,9,9,9,60,Avastin + TMZ, ,Avastin + Lomustine, 
10608,106081,US,1L,1953,62,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,9,9,9,9,9,95,TMZ mono, ,999, 
10608,106082,US,1L,1942,73,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,9,9,9,9,9,999,Avastin mono, ,999, 
10608,106083,US,2L,1952,63,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0, ,0,1,1,9,9,9,9,9,85,TMZ mono, ,Avastin mono, 
10608,106084,US,2L,1939,76,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0, ,0,2,2,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10608,106085,US,2L,1944,71,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10609,106091,US,1L,1940,75,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,0,1,0,1,999,Avastin mono, ,999, 
10609,106092,US,1L,1935,80,Female,Black/African,1,1,Passive / not interested / unengaged,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,1,1,1,1,1,999,Avastin mono, ,999, 
10609,106093,US,2L,1952,62,Male,Asian,0,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,0,0,9,9,999,Avastin mono, ,Avastin + Lomustine, 
10609,106094,US,2L,1963,51,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,1,1,0,1,0,999,TMZ mono, ,Avastin mono, 
10609,106095,US,2L,1939,75,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,1,1,0,0,999,Avastin mono, ,Avastin + Lomustine, 
10627,106271,US,1L,1958,61,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,100,TMZ mono, ,999, 
10627,106272,US,1L,1971,48,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,100,TMZ mono, ,999, 
10627,106273,US,2L,1941,78,Male,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicaid,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,98,TMZ mono, ,TMZ mono, 
10627,106274,US,2L,1980,39,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,100,TMZ mono, ,TMZ mono, 
10627,106275,US,2L,1969,50,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,99,TMZ mono, ,TMZ mono, 
10635,106351,US,1L,1945,70,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,999,Avastin mono, ,999, 
10635,106352,US,1L,1941,74,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0, ,0,1,9,9,9,9,9,9,999,Avastin mono, ,999, 
10635,106353,US,2L,1946,69,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,9,9,9,9,999,Lomustine mono, ,Avastin mono, 
10635,106354,US,2L,1950,65,Male,Asian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
10635,106355,US,2L,1955,60,Male,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,0,9,9,9,9,999,Lomustine mono, ,Avastin mono, 
10636,106361,US,1L,1950,65,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,9,1,0,0,9,9,90,TMZ mono, ,999, 
10636,106362,US,1L,1948,67,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,0,0,9,9,95,TMZ mono, ,999, 
10636,106363,US,2L,1945,69,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,1,1,0,0,0,9,9,90,Lomustine mono, ,Avastin mono, 
10636,106364,US,2L,1960,54,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,1,1,1,0,0,9,9,95,TMZ mono, ,Avastin + TMZ, 
10636,106365,US,2L,1952,62,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,1,1,0,0,0,9,9,90,Lomustine mono, ,Avastin + TMZ, 
10789,107891,US,1L,1952,63,Male,Asian,9,9,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,25,Avastin + Lomustine, ,999, 
10789,107892,US,1L,1956,59,Male,Asian,9,9,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,50,Avastin + Lomustine, ,999, 
10789,107893,US,2L,1963,52,Male,Black/African,9,9,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,50,Avastin + Irinotecan, ,Avastin + TMZ, 
10789,107894,US,2L,1967,48,Male,Black/African,9,9,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,9,9,9,9,999,Avastin + Lomustine, ,Avastin + Lomustine, 
10789,107895,US,2L,1945,70,Male,Black/African,9,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,999,Avastin + Irinotecan, ,Avastin + Irinotecan, 
10837,108371,US,1L,1965,54,Female,Spanish/Hispanic/Latino,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1, ,1,4,9,9,9,9,9,9,999,TMZ mono, ,999, 
10837,108372,US,1L,1965,54,Male,Black/African,0,0,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1, ,1,4,9,9,9,9,9,9,999,TMZ mono, ,999, 
10837,108373,US,2L,1965,54,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
10837,108374,US,2L,1944,75,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
10837,108375,US,2L,1945,74,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
10855,108551,US,1L,1962,53,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,HMO,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,0,9,0,0,9,0,0,80,Gliadel wafers, ,999, 
10855,108552,US,1L,1971,44,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,0,0,9,9,9,75,Lomustine mono, ,999, 
10855,108553,US,2L,1979,36,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,2,1,0,9,9,9,90,TMZ mono, ,Avastin + TMZ, 
10855,108554,US,2L,1966,48,Female,Spanish/Hispanic/Latino,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0, ,0,0,1,0,0,9,9,0,75,Gliadel wafers, ,Avastin + Irinotecan, 
10855,108555,US,2L,1955,59,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,0,0,9,9,0,100,Gliadel wafers, ,Avastin + TMZ, 
10917,109171,US,1L,1953,62,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,0,0,0,50,TMZ mono, ,999, 
10917,109172,US,1L,1963,52,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,1,0,0,0,0,999,Avastin mono, ,999, 
10917,109173,US,2L,1970,45,Male,Spanish/Hispanic/Latino,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,1,0,0,0,0,999,TMZ mono, ,Avastin mono, 
10917,109174,US,2L,1959,56,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,2,1,1,1,1,1,999,Avastin mono, ,Avastin + TMZ, 
10917,109175,US,2L,1980,35,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,0,0,0,25,TMZ mono, ,Avastin + TMZ, 
10925,109251,US,1L,1969,46,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,9,9,9,9,10,TMZ mono, ,999, 
10925,109252,US,1L,1969,46,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,9,9,9,9,20,Avastin mono, ,999, 
10925,109253,US,2L,1958,57,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,9,9,9,9,999,Avastin mono, ,Avastin + TMZ, 
10925,109254,US,2L,1951,64,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,1,9,9,9,9,999,TMZ mono, ,Avastin + Irinotecan, 
10925,109255,US,2L,1953,62,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,1,9,9,9,9,10,TMZ mono, ,Avastin + Irinotecan, 
11000,110001,US,1L,1956,59,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,0,0,9,9,9,95,Lomustine mono, ,999, 
11000,110002,US,1L,1950,65,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,0,0,9,9,9,96,Avastin mono, ,999, 
11000,110003,US,2L,1959,56,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,1,0,9,9,9,85,TMZ mono, ,Avastin + TMZ, 
11000,110004,US,2L,1963,52,Female,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,0,1,9,9,9,80,Avastin mono, ,Avastin + Lomustine, 
11000,110005,US,2L,1969,46,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,9,9,9,80,Lomustine mono, ,Avastin + Lomustine, 
11055,110551,US,1L,1964,51,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Uninsured,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,9,9,9,9,999,Avastin mono, ,999, 
11055,110552,US,1L,1947,68,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,VA/Other government,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,9,9,9,9,90,TMZ mono, ,999, 
11055,110553,US,2L,1955,60,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,VA/Other government,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,9,9,9,9,9,45,TMZ mono, ,Lomustine mono, 
11055,110554,US,2L,1961,54,Female,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Quality of Life,VA/Other government,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,85,TMZ mono, ,Lomustine mono, 
11055,110555,US,2L,1960,55,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,VA/Other government,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,999,TMZ mono, ,Lomustine mono, 
11125,111251,US,1L,1950,65,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,9,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,999,Avastin mono, ,999, 
11125,111252,US,1L,1950,64,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,9,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,0,2,9,9,9,9,9,9,999,Avastin + TMZ, ,999, 
11125,111253,US,2L,1950,64,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,9,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,9,9,9,9,99,Lomustine mono, ,Avastin + Irinotecan, 
11125,111254,US,2L,1947,67,Female,Asian,0,0,Average level of engagement with the disease,More focused on Quality of Life,9,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,9,9,9,9,999,TMZ mono, ,Avastin mono, 
11125,111255,US,2L,1956,58,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,9,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,9,9,9,9,999,Lomustine mono, ,Lomustine mono, 
11160,111601,US,1L,1991,24,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,0,0,1,50,Avastin + TMZ, ,999, 
11160,111602,US,1L,1970,45,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,0,1,0,9,0,65,Avastin + Irinotecan, ,999, 
11160,111603,US,2L,1944,69,Female,Black/African,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,2,2,9,9,9,9,9,75,Other,Irinotecan,Avastin + TMZ, 
11160,111604,US,2L,1951,63,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,2,0,0,9,9,9,999,Avastin + Irinotecan, ,Avastin + Lomustine, 
11160,111605,US,2L,1968,47,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,0,0,1,0,0,30,Avastin + Lomustine, ,Avastin + TMZ, 
11352,113521,US,1L,1967,52,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,95,TMZ mono, ,999, 
11352,113522,US,1L,1962,57,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,100,TMZ mono, ,999, 
11352,113523,US,2L,1952,67,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,95,TMZ mono, ,TMZ mono, 
11352,113524,US,2L,1939,80,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,90,TMZ mono, ,TMZ mono, 
11352,113525,US,2L,1973,46,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
11365,113651,US,1L,1950,65,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,1,0,0,9,9,999,Avastin + Lomustine, ,999, 
11365,113652,US,1L,1960,55,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,999,Avastin + Lomustine, ,999, 
11365,113653,US,2L,1945,70,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,2,9,9,9,9,9,999,Avastin + TMZ, ,Avastin + Lomustine, 
11365,113654,US,2L,1953,62,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,2,9,9,9,9,9,999,Avastin + Irinotecan, ,Avastin + Lomustine, 
11365,113655,US,2L,1964,51,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,999,Avastin + Lomustine, ,Avastin + TMZ, 
11366,113661,US,1L,1953,62,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0, ,0,1,9,9,0,9,9,9,999,Avastin mono, ,999, 
11366,113662,US,1L,1962,53,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0, ,0,0,9,9,1,9,9,9,35,TMZ mono, ,999, 
11366,113663,US,2L,1954,61,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,0,0,9,9,0,30,Gliadel wafers, ,Avastin + Lomustine, 
11366,113664,US,2L,1950,65,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,1,9,9,0,33,TMZ mono, ,Gliadel wafers, 
11366,113665,US,2L,1957,58,Female,Black/African,0,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0, ,0,1,1,1,0,9,9,0,999,Avastin mono, ,Avastin + TMZ, 
11395,113951,US,1L,1975,40,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,1,9,0,100,Avastin + TMZ, ,999, 
11395,113952,US,1L,1982,33,Female,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,1,0,0,100,Avastin + Irinotecan, ,999, 
11395,113953,US,2L,1980,34,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,1,0,1,0,0,1,100,Avastin + Lomustine, ,TMZ mono, 
11395,113954,US,2L,1983,31,Female,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,0,1,0,1,100,Avastin + Irinotecan, ,TMZ mono, 
11395,113955,US,2L,1976,37,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,1,1,1,100,Avastin + TMZ, ,Avastin mono, 
11439,114391,US,1L,1955,60,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,9,9,9,9,70,TMZ mono, ,999, 
11439,114392,US,1L,1950,65,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,70,TMZ mono, ,999, 
11439,114393,US,2L,1954,61,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,70,TMZ mono, ,Avastin mono, 
11439,114394,US,2L,1950,65,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,70,TMZ mono, ,Avastin mono, 
11439,114395,US,2L,1956,59,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,70,Avastin + Irinotecan, ,Avastin + Irinotecan, 
11620,116201,US,1L,1966,46,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,0,0,0,0,95,Avastin mono, ,999, 
11620,116202,US,1L,1977,38,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,0,0,0,0,99,Avastin + Irinotecan, ,999, 
11620,116203,US,2L,1955,57,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,1,1,0,0,0,99,Avastin + Irinotecan, ,Lomustine mono, 
11620,116204,US,2L,1971,42,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,0,0,0,0,90,Lomustine mono, ,Avastin + Irinotecan, 
11620,116205,US,2L,1966,48,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,3,0,0,1,0,0,80,Avastin + Irinotecan, ,TMZ mono, 
12025,120251,US,1L,1967,48,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,1,9,9,1,60,TMZ mono, ,999, 
12025,120252,US,1L,1972,43,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,1,0,1,0,75,Lomustine mono, ,999, 
12025,120253,US,2L,1963,50,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,0,0,0,1,35,TMZ mono, ,Avastin mono, 
12025,120254,US,2L,1956,55,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,0,0,0,0,999,TMZ mono, ,Avastin mono, 
12025,120255,US,2L,1950,60,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,1,0,0,0,999,TMZ mono, ,Avastin mono, 
12039,120391,US,1L,1955,60,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,0,0,0,0,80,TMZ mono, ,999, 
12039,120392,US,1L,1944,71,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,0,0,0,0,999,Avastin mono, ,999, 
12039,120393,US,2L,1955,60,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,0,0,0,0,0,999,Lomustine mono, ,Avastin mono, 
12039,120394,US,2L,1959,56,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,0,0,0,0,999,Avastin mono, ,TMZ mono, 
12039,120395,US,2L,1956,59,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,0,0,0,0,999,Avastin mono, ,TMZ mono, 
12060,120601,US,1L,1956,63,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,50,TMZ mono, ,999, 
12060,120602,US,1L,1963,56,Male,Spanish/Hispanic/Latino,1,0,Active / knowledgeable / questioning,More focused on Survival,Uninsured,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,90,TMZ mono, ,999, 
12060,120603,US,2L,1949,70,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
12060,120604,US,2L,1978,41,Female,White/Caucasian,1,9,Active / knowledgeable / questioning,More focused on Survival,Uninsured,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,60,TMZ mono, ,TMZ mono, 
12060,120605,US,2L,1960,59,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,100,TMZ mono, ,TMZ mono, 
12062,120621,US,1L,1944,71,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,9,1,1,9,9,85,TMZ mono, ,999, 
12062,120622,US,1L,1940,75,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,9,9,9,9,9,95,TMZ mono, ,999, 
12062,120623,US,2L,1950,65,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,90,TMZ mono, ,Avastin + Irinotecan, 
12062,120624,US,2L,1946,69,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,75,TMZ mono, ,Avastin + Irinotecan, 
12062,120625,US,2L,1958,57,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0, ,0,2,2,9,9,9,9,9,999,TMZ mono, ,Avastin + Irinotecan, 
12618,126181,US,1L,1954,61,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,9,9,0,9,95,Lomustine mono, ,999, 
12618,126182,US,1L,1937,78,Male,White/Caucasian,0,1,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,0,9,9,0,9,90,TMZ mono, ,999, 
12618,126183,US,2L,1942,73,Male,Spanish/Hispanic/Latino,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,9,9,0,9,999,Avastin mono, ,Avastin + Irinotecan, 
12618,126184,US,2L,1946,69,Female,Asian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,9,9,0,9,95,Lomustine mono, ,Avastin mono, 
12618,126185,US,2L,1960,55,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,0,9,999,Avastin mono, ,Avastin + Irinotecan, 
12653,126531,US,1L,1964,51,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,1,0,9,9,9,100,Avastin + Irinotecan, ,999, 
12653,126532,US,1L,1949,66,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,2,9,0,0,9,9,9,100,Avastin + Irinotecan, ,999, 
12653,126533,US,2L,1949,66,Male,Black/African,9,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0, ,0,2,3,0,0,9,9,9,85,Avastin + Irinotecan, ,Avastin + TMZ, 
12653,126534,US,2L,1943,72,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,3,4,0,0,9,9,9,84,Avastin mono, ,Avastin + Lomustine, 
12653,126535,US,2L,1957,58,Male,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,0,9,9,9,87,Avastin mono, ,Avastin + Irinotecan, 
12700,127001,US,1L,1938,77,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,VA/Other government,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,100,TMZ mono, ,999, 
12700,127002,US,1L,1979,36,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,9,9,9,9,100,TMZ mono, ,999, 
12700,127003,US,2L,1950,64,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,9,9,1,9,999,TMZ mono, ,Avastin + TMZ, 
12700,127004,US,2L,1942,73,Male,White/Caucasian,1,1,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
12700,127005,US,2L,1966,48,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,9,9,1,9,100,Lomustine mono, ,Avastin + TMZ, 
12701,127011,US,1L,1993,26,Female,Spanish/Hispanic/Latino,1,9,Average level of engagement with the disease,More focused on Quality of Life,9,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,100,TMZ mono, ,999, 
12701,127012,US,1L,1982,37,Female,White/Caucasian,1,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,75,TMZ mono, ,999, 
12701,127013,US,2L,1944,75,Male,Asian,9,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,80,TMZ mono, ,TMZ mono, 
12701,127014,US,2L,1977,42,Female,Asian,1,9,Active / knowledgeable / questioning,More focused on Quality of Life,9,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,100,TMZ mono, ,TMZ mono, 
12701,127015,US,2L,1955,64,Male,Other,0,9,Passive / not interested / unengaged,More focused on Quality of Life,9,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,75,TMZ mono, ,TMZ mono, 
12725,127251,US,1L,1965,50,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,0,9,9,9,9,65,TMZ mono, ,999, 
12725,127252,US,1L,1965,50,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,9,9,9,9,50,Lomustine mono, ,999, 
12725,127253,US,2L,1957,58,Female,White/Caucasian,1,1,Passive / not interested / unengaged,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,3,0,9,9,9,9,40,Lomustine mono, ,Avastin + TMZ, 
12725,127254,US,2L,1949,66,Male,White/Caucasian,1,1,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,9,9,9,9,9,55,TMZ mono, ,Avastin + TMZ, 
12725,127255,US,2L,1940,75,Male,White/Caucasian,1,1,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,0,1,3,0,9,9,9,9,50,TMZ mono, ,Avastin + TMZ, 
12729,127291,US,1L,1996,19,Female,Spanish/Hispanic/Latino,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,3,9,9,9,9,9,9,20,TMZ mono, ,999, 
12729,127292,US,1L,1994,21,Male,Spanish/Hispanic/Latino,9,1,Passive / not interested / unengaged,More focused on Quality of Life,Medicaid,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,4,9,9,9,9,9,9,999,Avastin mono, ,999, 
12729,127293,US,2L,1992,23,Female,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,9,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,3,9,9,9,9,9,999,TMZ mono, ,Avastin + TMZ, 
12729,127294,US,2L,1996,19,Female,Spanish/Hispanic/Latino,9,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicaid,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,9,9,9,9,9,999,TMZ mono, ,Avastin + TMZ, 
12729,127295,US,2L,1991,24,Female,Spanish/Hispanic/Latino,0,1,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,9,9,9,9,999,TMZ mono, ,Avastin + TMZ, 
12740,127401,US,1L,1976,39,Male,White/Caucasian,0,9,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,1,0,0,9,0,80,TMZ mono, ,999, 
12740,127402,US,1L,1949,66,Male,Black/African,1,9,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,1,1,1,1,1,70,TMZ mono, ,999, 
12740,127403,US,2L,1948,67,Male,Black/African,1,9,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,3,1,1,1,9,9,70,TMZ mono, ,Avastin mono, 
12740,127404,US,2L,1948,67,Male,Black/African,1,9,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,3,1,1,1,9,9,999,TMZ mono, ,Avastin mono, 
12740,127405,US,2L,1949,66,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,3,3,1,9,9,9,9,999,TMZ mono, ,Lomustine mono, 
12750,127501,US,1L,1977,37,Male,White/Caucasian,9,9,Average level of engagement with the disease,More focused on Quality of Life,9,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,9,9,9,9,85,TMZ mono, ,999, 
12750,127502,US,1L,1965,49,Female,Other,1,9,Average level of engagement with the disease,More focused on Survival,9,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0, ,0,2,9,9,9,9,9,9,999,Avastin mono, ,999, 
12750,127503,US,2L,1950,63,Female,White/Caucasian,1,9,Average level of engagement with the disease,More focused on Quality of Life,9,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,1,9,9,1,90,TMZ mono, ,Lomustine mono, 
12750,127504,US,2L,1970,44,Female,Black/African,1,9,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0, ,0,2,1,9,9,9,9,9,78,TMZ mono, ,Lomustine mono, 
12750,127505,US,2L,1967,45,Female,White/Caucasian,9,9,Average level of engagement with the disease,More focused on Survival,9,1,1,1,1,0,1,0,0,0,1,1,1,0,0,0, ,0,2,2,0,1,1,9,9,90,Lomustine mono, ,TMZ mono, 
12764,127641,US,1L,1947,67,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,0,1,0,999,Avastin + TMZ, ,999, 
12764,127642,US,1L,1951,64,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,1,0,0,0,999,Avastin mono, ,999, 
12764,127643,US,2L,1938,75,Female,Asian,9,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,1,1,0,0,1,25,Avastin + TMZ, ,Avastin + Irinotecan, 
12764,127644,US,2L,1944,70,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,1,0,1,0,0,10,TMZ mono, ,Avastin + Lomustine, 
12764,127645,US,2L,1925,88,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Quality of Life,Uninsured,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0, ,0,1,2,1,1,0,0,0,999,Avastin + Irinotecan, ,Avastin + TMZ, 
12811,128111,US,1L,1940,79,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,99,TMZ mono, ,999, 
12811,128112,US,1L,1941,78,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,99,TMZ mono, ,999, 
12811,128113,US,2L,1943,76,Female,Black/African,1,1,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
12811,128114,US,2L,1940,79,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,90,TMZ mono, ,TMZ mono, 
12811,128115,US,2L,1942,77,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,95,TMZ mono, ,TMZ mono, 
12920,129201,US,1L,1959,56,Male,White/Caucasian,9,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,1,9,9,9,9,80,TMZ mono, ,999, 
12920,129202,US,1L,1943,72,Male,Spanish/Hispanic/Latino,9,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,60,TMZ mono, ,999, 
12920,129203,US,2L,1956,59,Female,White/Caucasian,9,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,2,1,9,9,9,9,999,TMZ mono, ,Avastin mono, 
12920,129204,US,2L,1961,54,Male,Black/African,9,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,2,0,9,9,9,9,50,Lomustine mono, ,Avastin mono, 
12920,129205,US,2L,1950,65,Male,Spanish/Hispanic/Latino,9,9,Average level of engagement with the disease,More focused on Survival,9,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,2,2,1,9,9,9,9,999,TMZ mono, ,Avastin mono, 
12923,129231,US,1L,1945,70,Male,White/Caucasian,9,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,9,9,9,9,9,999,Avastin mono, ,999, 
12923,129232,US,1L,1946,69,Female,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,9,9,9,9,9,999,Avastin mono, ,999, 
12923,129233,US,2L,1944,71,Male,Black/African,9,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,9,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
12923,129234,US,2L,1943,72,Male,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,9,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
12923,129235,US,2L,1942,73,Female,Asian,9,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,9,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
12930,129301,US,1L,1966,49,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,9,9,9,9,90,TMZ mono, ,999, 
12930,129302,US,1L,1962,53,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,9,1,9,9,9,9,80,TMZ mono, ,999, 
12930,129303,US,2L,1969,45,Male,Black/African,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,1,9,9,9,9,80,TMZ mono, ,Avastin mono, 
12930,129304,US,2L,1965,50,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,9,9,9,9,70,TMZ mono, ,Avastin mono, 
12930,129305,US,2L,1966,49,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,1,9,9,9,9,70,TMZ mono, ,Avastin mono, 
12932,129321,US,1L,1950,65,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,1,0,1,9,9,100,TMZ mono, ,999, 
12932,129322,US,1L,1944,71,Female,White/Caucasian,1,1,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,0,0,1,9,9,40,Lomustine mono, ,999, 
12932,129323,US,2L,1948,66,Female,Asian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,2,1,1,0,0,9,9,100,TMZ mono, ,Avastin mono, 
12932,129324,US,2L,1954,59,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,0,9,9,9,100,TMZ mono, ,Avastin + Irinotecan, 
12932,129325,US,2L,1950,63,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,9,9,9,100,Lomustine mono, ,Avastin + Irinotecan, 
12936,129361,US,1L,1929,86,Male,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,1,9,9,9,9,999,Avastin mono, ,999, 
12936,129362,US,1L,1950,65,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,9,9,9,9,90,TMZ mono, ,999, 
12936,129363,US,2L,1955,60,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,9,9,9,9,90,TMZ mono, ,Avastin mono, 
12936,129364,US,2L,1967,48,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,1,9,9,9,9,999,TMZ mono, ,Avastin mono, 
12936,129365,US,2L,1955,60,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,Medicaid,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,9,9,9,9,90,TMZ mono, ,Avastin mono, 
12943,129431,US,1L,1944,71,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,9,9,9,9,80,TMZ mono, ,999, 
12943,129432,US,1L,1939,76,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,0,9,9,9,9,90,Lomustine mono, ,999, 
12943,129433,US,2L,1945,70,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,0,0,9,9,9,9,90,Lomustine mono, ,Avastin mono, 
12943,129434,US,2L,1938,77,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,0,9,9,9,9,70,Lomustine mono, ,Lomustine mono, 
12943,129435,US,2L,1942,73,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,0,9,9,9,9,85,Lomustine mono, ,Lomustine mono, 
12944,129441,US,1L,1962,53,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,1,0,0,1,1,0,1,0,1,1,0,0,0, ,0,2,9,9,9,9,9,9,90,TMZ mono, ,999, 
12944,129442,US,1L,1953,62,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0, ,0,1,9,9,9,9,9,9,80,TMZ mono, ,999, 
12944,129443,US,2L,1950,64,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,HMO,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0, ,0,1,1,9,9,9,9,9,90,TMZ mono, ,Avastin mono, 
12944,129444,US,2L,1953,61,Male,Asian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0, ,0,1,1,9,9,9,9,9,95,TMZ mono, ,Avastin mono, 
12944,129445,US,2L,1961,53,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Exchange,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0, ,0,1,1,9,9,9,9,9,85,TMZ mono, ,Avastin mono, 
12959,129591,US,1L,1939,76,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,0,0,0,0,999,Avastin mono, ,999, 
12959,129592,US,1L,1938,77,Male,Black/African,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,0,0,0,0,999,Avastin mono, ,999, 
12959,129593,US,2L,1938,77,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,1,0,0,0,0,999,Avastin mono, ,Lomustine mono, 
12959,129594,US,2L,1938,77,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,1,0,0,0,0,999,Avastin mono, ,Lomustine mono, 
12959,129595,US,2L,1938,77,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,1,0,0,0,0,999,Avastin mono, ,Lomustine mono, 
12964,129641,US,1L,1963,52,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,1,1,9,100,TMZ mono, ,999, 
12964,129642,US,1L,1955,60,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,0,1,0,9,100,TMZ mono, ,999, 
12964,129643,US,2L,1958,56,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,0,1,0,9,90,Lomustine mono, ,Avastin mono, 
12964,129644,US,2L,1962,52,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,0,0,0,9,999,Avastin mono, ,Avastin + Irinotecan, 
12964,129645,US,2L,1960,54,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,0,1,0,9,999,Avastin mono, ,Avastin + Irinotecan, 
13045,130451,US,1L,1979,40,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,80,TMZ mono, ,999, 
13045,130452,US,1L,1975,44,Male,Spanish/Hispanic/Latino,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,85,TMZ mono, ,999, 
13045,130453,US,2L,1968,51,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,70,TMZ mono, ,TMZ mono, 
13045,130454,US,2L,1972,47,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,80,TMZ mono, ,TMZ mono, 
13045,130455,US,2L,1962,57,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,65,TMZ mono, ,TMZ mono, 
13089,130891,US,1L,1961,54,Male,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,9,9,9,9,90,TMZ mono, ,999, 
13089,130892,US,1L,1960,55,Female,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,0,9,9,9,9,95,Lomustine mono, ,999, 
13089,130893,US,2L,1952,62,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,1,9,9,9,9,60,TMZ mono, ,Avastin mono, 
13089,130894,US,2L,1957,57,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0, ,0,1,1,1,9,9,9,9,60,TMZ mono, ,Avastin mono, 
13089,130895,US,2L,1948,66,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,1,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13120,131201,US,1L,1955,60,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,0,9,9,9,9,999,Avastin mono, ,999, 
13120,131202,US,1L,1945,70,Male,White/Caucasian,9,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0, ,0,3,9,9,9,9,9,9,999,Avastin mono, ,999, 
13120,131203,US,2L,1942,73,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,9,9,9,9,9,999,Avastin mono, ,Avastin + TMZ, 
13120,131204,US,2L,1941,73,Female,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,3,4,9,9,9,9,9,999,Avastin mono, ,Avastin + TMZ, 
13120,131205,US,2L,1960,54,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,40,TMZ mono, ,Gliadel wafers, 
13122,131221,US,1L,1956,59,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,999,Avastin mono, ,999, 
13122,131222,US,1L,1947,68,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,999,Avastin mono, ,999, 
13122,131223,US,2L,1982,33,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,9,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
13122,131224,US,2L,1935,80,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,3,9,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
13122,131225,US,2L,1956,59,Male,Black/African,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,3,9,9,9,9,9,999,Avastin mono, ,Lomustine mono, 
13131,131311,US,1L,1970,45,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,1,0,0,0,999,Avastin mono, ,999, 
13131,131312,US,1L,1962,53,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,0,0,1,0,0,999,Avastin mono, ,999, 
13131,131313,US,2L,1966,48,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,0,0,0,0,999,Avastin mono, ,Avastin + Lomustine, 
13131,131314,US,2L,1959,54,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,0,1,0,0,0,999,Lomustine mono, ,Avastin mono, 
13131,131315,US,2L,1954,52,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,0,0,1,1,999,Lomustine mono, ,Avastin mono, 
13135,131351,US,1L,1976,39,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,9,9,9,9,65,Avastin + Irinotecan, ,999, 
13135,131352,US,1L,1962,52,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,1,0,0,1,25,Avastin mono, ,999, 
13135,131353,US,2L,1979,36,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,999,Avastin + Irinotecan, ,Lomustine mono, 
13135,131354,US,2L,1962,53,Male,White/Caucasian,0,1,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0, ,0,0,1,0,9,1,0,1,999,Avastin mono, ,Avastin + Irinotecan, 
13135,131355,US,2L,1987,28,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,1,0,0,9,999,Avastin mono, ,Lomustine mono, 
13141,131411,US,1L,1962,53,Male,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Quality of Life,9,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,9,9,9,9,9,70,TMZ mono, ,999, 
13141,131412,US,1L,1956,59,Male,Black/African,9,1,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0, ,0,2,9,9,9,9,9,9,80,TMZ mono, ,999, 
13141,131413,US,2L,1950,65,Female,White/Caucasian,9,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0, ,0,2,3,9,9,9,9,9,60,TMZ mono, ,Avastin + Irinotecan, 
13141,131414,US,2L,1960,54,Male,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,9,9,9,9,75,Lomustine mono, ,Avastin + TMZ, 
13141,131415,US,2L,1948,66,Female,Black/African,9,1,Passive / not interested / unengaged,More focused on Survival,Medicare,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0, ,0,2,3,9,9,9,9,9,60,TMZ mono, ,Avastin + Lomustine, 
13170,131701,US,1L,1961,52,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,0,9,0,1,0,0,0,90,Lomustine mono, ,999, 
13170,131702,US,1L,1981,33,Male,Asian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,0,1,0,0,65,Lomustine mono, ,999, 
13170,131703,US,2L,1971,43,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0, ,0,1,2,0,0,9,9,9,45,Avastin mono, ,Avastin + Lomustine, 
13170,131704,US,2L,1965,49,Female,Asian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,1,0,0,0,35,Avastin mono, ,Avastin + Lomustine, 
13170,131705,US,2L,1956,56,Female,Black/African,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,3,1,0,0,0,0,0,64,Lomustine mono, ,Avastin + Irinotecan, 
13174,131741,US,1L,1954,61,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,95,TMZ mono, ,999, 
13174,131742,US,1L,1959,56,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,999,Avastin mono, ,999, 
13174,131743,US,2L,1948,67,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,100,TMZ mono, ,Avastin mono, 
13174,131744,US,2L,1955,60,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13174,131745,US,2L,1944,71,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13178,131781,US,1L,1937,78,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,9,9,9,9,9,100,TMZ mono, ,999, 
13178,131782,US,1L,1948,67,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0, ,0,0,9,9,9,9,9,9,50,TMZ mono, ,999, 
13178,131783,US,2L,1932,83,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13178,131784,US,2L,1944,70,Male,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Survival,Medicare,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13178,131785,US,2L,1955,60,Female,Asian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,100,TMZ mono, ,Avastin mono, 
13209,132091,US,1L,1955,60,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,9,9,9,9,9,90,TMZ mono, ,999, 
13209,132092,US,1L,1948,67,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,2,9,9,9,9,9,9,90,TMZ mono, ,999, 
13209,132093,US,2L,1962,51,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,9,9,9,9,90,TMZ mono, ,Avastin + TMZ, 
13209,132094,US,2L,1936,78,Male,Asian,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,3,9,9,9,9,9,80,TMZ mono, ,Avastin mono, 
13209,132095,US,2L,1950,64,Female,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,95,TMZ mono, ,Avastin + TMZ, 
13210,132101,US,1L,1945,70,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,9,9,9,9,60,Lomustine mono, ,999, 
13210,132102,US,1L,1951,64,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,9,9,9,9,100,Lomustine mono, ,999, 
13210,132103,US,2L,1953,61,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,0,9,9,9,9,100,Lomustine mono, ,Avastin mono, 
13210,132104,US,2L,1942,73,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13210,132105,US,2L,1960,54,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,9,9,9,9,100,Lomustine mono, ,Avastin mono, 
13263,132631,US,1L,1955,64,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,999,TMZ mono, ,999, 
13263,132632,US,1L,1955,64,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,999,TMZ mono, ,999, 
13263,132633,US,2L,1945,74,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
13263,132634,US,2L,1966,53,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
13263,132635,US,2L,1955,64,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
13269,132691,US,1L,1966,49,Female,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,0,0,0,0,0,90,TMZ mono, ,999, 
13269,132692,US,1L,1970,45,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,1,0,0,1,0,90,TMZ mono, ,999, 
13269,132693,US,2L,1969,46,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,1,0,0,0,0,90,TMZ mono, ,Avastin + Irinotecan, 
13269,132694,US,2L,1971,43,Female,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,1,0,0,0,0,90,TMZ mono, ,Avastin + TMZ, 
13269,132695,US,2L,1971,43,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,1,0,80,TMZ mono, ,Avastin + TMZ, 
13270,132701,US,1L,1950,65,Male,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,999,Avastin + Irinotecan, ,999, 
13270,132702,US,1L,1968,47,Male,White/Caucasian,9,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,999,Avastin + Irinotecan, ,999, 
13270,132703,US,2L,1975,40,Female,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,0,0,0,0,999,Avastin + Irinotecan, ,TMZ mono, 
13270,132704,US,2L,1980,35,Female,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,9,9,9,9,999,Avastin + Irinotecan, ,TMZ mono, 
13270,132705,US,2L,1955,60,Male,White/Caucasian,9,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,999,Avastin + Irinotecan, ,TMZ mono, 
13271,132711,US,1L,1949,66,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0, ,0,1,9,1,0,0,1,1,90,TMZ mono, ,999, 
13271,132712,US,1L,1939,76,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Survival,Medicare,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,1,0,1,0,80,TMZ mono, ,999, 
13271,132713,US,2L,1952,63,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,1,1,0,0,75,TMZ mono, ,Avastin + Irinotecan, 
13271,132714,US,2L,1955,60,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Survival,Medicaid,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0, ,0,1,2,0,1,0,0,0,90,TMZ mono, ,Avastin mono, 
13271,132715,US,2L,1929,86,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,3,0,0,1,1,0,85,Lomustine mono, ,Other,bevacizumab
13280,132801,US,1L,1966,48,Male,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,0,1,9,0,999,Avastin + Lomustine, ,999, 
13280,132802,US,1L,1977,38,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,1,9,1,1,999,Avastin mono, ,999, 
13280,132803,US,2L,1966,49,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,1,0,1,0,9,9,44,Avastin + Irinotecan, ,Avastin mono, 
13280,132804,US,2L,1977,37,Male,Black/African,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,0,2,1,1,1,0,0,9,99,Avastin mono, ,Avastin + Irinotecan, 
13280,132805,US,2L,1966,48,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,1,1,1,0,77,Avastin mono, ,Avastin + Lomustine, 
13302,133021,US,1L,1955,60,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,9,1,9,9,9,9,90,TMZ mono, ,999, 
13302,133022,US,1L,1959,56,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,9,9,9,9,100,Lomustine mono, ,999, 
13302,133023,US,2L,1962,51,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,1,9,9,9,9,100,TMZ mono, ,Avastin + Irinotecan, 
13302,133024,US,2L,1945,68,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,obesity,0,1,1,1,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13302,133025,US,2L,1942,72,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,parkinson's disease,0,1,2,0,9,9,9,9,999,Avastin mono, ,Avastin + Lomustine, 
13304,133041,US,1L,1956,59,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,9,1,0,0,0,0,95,TMZ mono, ,999, 
13304,133042,US,1L,1961,54,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,0,9,0,9,100,TMZ mono, ,999, 
13304,133043,US,2L,1956,58,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,1,0,9,9,9,80,TMZ mono, ,Avastin + Irinotecan, 
13304,133044,US,2L,1966,48,Female,Black/African,1,0,Passive / not interested / unengaged,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,1,0,9,9,9,100,TMZ mono, ,Avastin + Irinotecan, 
13304,133045,US,2L,1964,50,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,1,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13307,133071,US,1L,1996,19,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,VA/Other government,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,1,0,0,85,Lomustine mono, ,999, 
13307,133072,US,1L,1988,26,Male,Asian,9,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0, ,0,2,9,0,1,1,0,0,85,TMZ mono, ,999, 
13307,133073,US,2L,1981,32,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,3,1,0,1,0,0,90,TMZ mono, ,Avastin + Irinotecan, 
13307,133074,US,2L,1978,32,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,VA/Other government,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,1,1,0,1,96,TMZ mono, ,Avastin + TMZ, 
13307,133075,US,2L,1974,38,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,Exchange,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0, ,0,1,2,1,0,1,0,1,90,TMZ mono, ,Avastin + Lomustine, 
13310,133101,US,1L,1950,56,Male,Asian,1,9,Active / knowledgeable / questioning,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,50,TMZ mono, ,999, 
13310,133102,US,1L,1955,51,Female,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,50,TMZ mono, ,999, 
13310,133103,US,2L,1960,43,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,50,TMZ mono, ,TMZ mono, 
13310,133104,US,2L,1965,38,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,9,9,9,9,50,TMZ mono, ,TMZ mono, 
13310,133105,US,2L,1970,32,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,9,9,9,9,50,TMZ mono, ,TMZ mono, 
13312,133121,US,1L,1954,61,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0, ,0,0,9,1,1,9,1,0,999,Avastin mono, ,999, 
13312,133122,US,1L,1968,47,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,0,0,0,1,1,999,Avastin + TMZ, ,999, 
13312,133123,US,2L,1973,41,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0, ,0,4,1,0,0,1,0,1,90,TMZ mono, ,Avastin + TMZ, 
13312,133124,US,2L,1952,62,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,PPO,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0, ,0,1,2,0,0,1,1,1,80,TMZ mono, ,Avastin + Irinotecan, 
13312,133125,US,2L,1955,58,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,0,0,9,0,95,TMZ mono, ,Avastin + TMZ, 
13313,133131,US,1L,1965,49,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,9,1,9,9,999,Avastin mono, ,999, 
13313,133132,US,1L,1970,45,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,9,9,9,9,9,999,Lomustine mono, ,999, 
13313,133133,US,2L,1966,49,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,9,9,9,9,9,999,Lomustine mono, ,Avastin + Irinotecan, 
13313,133134,US,2L,1955,60,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,9,9,9,9,999,Avastin mono, ,Avastin + Irinotecan, 
13313,133135,US,2L,1968,47,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,999,Avastin mono, ,Avastin + Irinotecan, 
13318,133181,US,1L,1966,53,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,56,TMZ mono, ,999, 
13318,133182,US,1L,1955,64,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0, ,1,4,9,9,9,9,9,9,999,TMZ mono, ,999, 
13318,133183,US,2L,1945,74,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
13318,133184,US,2L,1976,43,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,76,TMZ mono, ,TMZ mono, 
13318,133185,US,2L,1974,45,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
13328,133281,US,1L,1950,57,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,50,TMZ mono, ,999, 
13328,133282,US,1L,1955,52,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,50,TMZ mono, ,999, 
13328,133283,US,2L,1960,42,Male,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,9,9,9,9,50,TMZ mono, ,TMZ mono, 
13328,133284,US,2L,1965,37,Male,White/Caucasian,9,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,9,9,9,9,50,TMZ mono, ,TMZ mono, 
13328,133285,US,2L,1970,32,Male,White/Caucasian,9,9,Passive / not interested / unengaged,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,9,9,9,9,9,50,TMZ mono, ,TMZ mono, 
13332,133321,US,1L,1955,60,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,0,1,1,1,0,70,Avastin mono, ,999, 
13332,133322,US,1L,1951,64,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0, ,0,1,9,0,1,0,0,1,999,Avastin mono, ,999, 
13332,133323,US,2L,1949,66,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicaid,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0, ,0,0,0,1,1,0,1,0,80,Avastin mono, ,Avastin + Lomustine, 
13332,133324,US,2L,1945,70,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,1,1,1,1,0,80,Avastin + Irinotecan, ,Avastin + Lomustine, 
13332,133325,US,2L,1948,67,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,1,0,0,0,95,Avastin + Irinotecan, ,Avastin + Lomustine, 
13335,133351,US,1L,1945,70,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,0,9,9,9,30,TMZ mono, ,999, 
13335,133352,US,1L,1960,55,Female,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,1,0,9,9,50,Avastin + TMZ, ,999, 
13335,133353,US,2L,1952,63,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0, ,0,1,2,1,1,0,9,9,40,TMZ mono, ,Avastin + TMZ, 
13335,133354,US,2L,1965,50,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,1,0,0,1,50,Avastin mono, ,Avastin + Irinotecan, 
13335,133355,US,2L,1948,67,Male,Black/African,0,0,Passive / not interested / unengaged,More focused on Survival,Medicare,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,9,9,9,9,9,40,Avastin mono, ,Avastin + TMZ, 
13337,133371,US,1L,1950,65,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,1,9,9,9,80,TMZ mono, ,999, 
13337,133372,US,1L,1945,70,Male,White/Caucasian,1,1,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0, ,0,2,9,0,9,9,9,9,60,Lomustine mono, ,999, 
13337,133373,US,2L,1955,60,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,9,9,9,9,9,70,TMZ mono, ,Avastin + TMZ, 
13337,133374,US,2L,1968,47,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,9,9,9,9,80,TMZ mono, ,Avastin + Irinotecan, 
13337,133375,US,2L,1950,65,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,1,1,9,9,9,999,TMZ mono, ,Avastin mono, 
13340,133401,US,1L,1965,50,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,0,9,9,9,999,Avastin mono, ,999, 
13340,133402,US,1L,1956,59,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0, ,0,1,9,9,0,9,9,9,35,TMZ mono, ,999, 
13340,133403,US,2L,1963,52,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,0,1,9,9,0,25,TMZ mono, ,Avastin + TMZ, 
13340,133404,US,2L,1946,69,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0, ,0,1,3,1,0,9,9,0,60,TMZ mono, ,Lomustine mono, 
13340,133405,US,2L,1947,68,Male,Spanish/Hispanic/Latino,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0, ,0,1,2,0,0,9,9,1,999,Avastin mono, ,TMZ mono, 
13344,133441,US,1L,1953,62,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,0,0,0,9,9,90,Avastin + TMZ, ,999, 
13344,133442,US,1L,1944,71,Male,Black/African,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,0,1,9,9,999,Avastin mono, ,999, 
13344,133443,US,2L,1951,64,Female,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,0,1,9,9,95,TMZ mono, ,Avastin + TMZ, 
13344,133444,US,2L,1942,73,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,0,0,9,9,95,TMZ mono, ,Avastin + Irinotecan, 
13344,133445,US,2L,1955,60,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,1,9,9,95,TMZ mono, ,Avastin + TMZ, 
13347,133471,US,1L,1948,67,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,9,9,9,9,90,TMZ mono, ,999, 
13347,133472,US,1L,1953,62,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,9,9,9,9,100,TMZ mono, ,999, 
13347,133473,US,2L,1944,71,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,HMO,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0, ,0,0,0,1,9,9,9,9,100,TMZ mono, ,Avastin mono, 
13347,133474,US,2L,1946,69,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,1,1,9,9,9,9,100,TMZ mono, ,TMZ mono, 
13347,133475,US,2L,1965,50,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,1,9,9,9,9,90,TMZ mono, ,TMZ mono, 
13348,133481,US,1L,1956,55,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0, ,0,2,9,0,9,9,9,0,75,Avastin + Irinotecan, ,999, 
13348,133482,US,1L,1965,49,Female,White/Caucasian,1,9,Passive / not interested / unengaged,More focused on Survival,Medicaid,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0, ,0,2,9,1,0,0,9,9,86,TMZ mono, ,999, 
13348,133483,US,2L,1976,39,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0, ,0,1,2,1,0,1,9,0,88,Avastin mono, ,Avastin + Lomustine, 
13348,133484,US,2L,1976,39,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,Other,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0, ,0,1,3,0,0,9,9,9,66,Avastin mono, ,Avastin + Irinotecan, 
13348,133485,US,2L,1983,32,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Uninsured,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0, ,0,1,0,0,9,0,9,0,55,Lomustine mono, ,Avastin + Lomustine, 
13350,133501,US,1L,1965,50,Male,White/Caucasian,9,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,70,TMZ mono, ,999, 
13350,133502,US,1L,1953,62,Male,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,9,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,3,9,0,9,9,9,9,999,Avastin mono, ,999, 
13350,133503,US,2L,1950,65,Male,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,9,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,3,3,0,9,9,9,9,999,Avastin mono, ,Avastin + TMZ, 
13350,133504,US,2L,1962,53,Male,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,9,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,2,3,1,9,9,9,9,999,Avastin mono, ,Avastin + TMZ, 
13350,133505,US,2L,1961,54,Male,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Quality of Life,9,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,3,1,9,9,9,9,70,TMZ mono, ,Avastin + TMZ, 
13351,133511,US,1L,1955,60,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,0,9,9,9,999,Avastin mono, ,999, 
13351,133512,US,1L,1958,57,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,0,0,0,0,95,TMZ mono, ,999, 
13351,133513,US,2L,1952,63,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,PPO,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,0,0,0,75,TMZ mono, ,Avastin + Lomustine, 
13351,133514,US,2L,1954,61,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,0,0,0,80,TMZ mono, ,Avastin + Irinotecan, 
13351,133515,US,2L,1948,67,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,0,0,0,90,TMZ mono, ,Avastin + Lomustine, 
13357,133571,US,1L,1971,44,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,1,0,1,100,Lomustine mono, ,999, 
13357,133572,US,1L,1959,56,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0, ,0,2,9,9,9,9,9,9,90,TMZ mono, ,999, 
13357,133573,US,2L,1944,70,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,3,9,9,9,9,9,85,TMZ mono, ,Avastin mono, 
13357,133574,US,2L,1943,72,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Survival,Medicare,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0, ,0,1,3,9,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13357,133575,US,2L,1960,53,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0, ,0,0,2,0,9,9,9,9,100,Lomustine mono, ,Avastin + TMZ, 
13358,133581,US,1L,1946,67,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,1,0,0,9,9,90,TMZ mono, ,999, 
13358,133582,US,1L,1940,75,Female,White/Caucasian,1,9,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,1,9,1,0,1,9,9,100,Avastin + TMZ, ,999, 
13358,133583,US,2L,1935,80,Female,White/Caucasian,0,9,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0, ,0,2,3,0,0,0,9,9,999,Avastin mono, ,Avastin + Irinotecan, 
13358,133584,US,2L,1931,83,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0, ,0,2,3,0,0,1,9,9,95,Lomustine mono, ,Avastin + TMZ, 
13358,133585,US,2L,1947,68,Male,Spanish/Hispanic/Latino,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,1,1,0,0,0,0,100,TMZ mono, ,Avastin + Irinotecan, 
13367,133671,US,1L,1955,60,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,arthritis,0,1,9,0,0,1,0,9,30,Avastin + TMZ, ,999, 
13367,133672,US,1L,1950,65,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,aortic aneurysm,0,1,9,1,0,9,0,9,98,Avastin + TMZ, ,999, 
13367,133673,US,2L,1958,52,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,1,0,1,0,9,90,TMZ mono, ,Avastin + TMZ, 
13367,133674,US,2L,1968,46,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,1,0,1,0,9,999,Avastin + TMZ, ,Avastin + Irinotecan, 
13367,133675,US,2L,1965,40,Female,Asian,1,0,Average level of engagement with the disease,More focused on Survival,VA/Other government,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,1,0,0,0,9,98,TMZ mono, ,Avastin + TMZ, 
13381,133811,US,1L,1968,47,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,9,9,9,9,90,TMZ mono, ,999, 
13381,133812,US,1L,1960,55,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,9,9,9,9,95,TMZ mono, ,999, 
13381,133813,US,2L,1966,49,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,9,9,9,9,85,Lomustine mono, ,Avastin mono, 
13381,133814,US,2L,1951,63,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,1,9,9,9,9,100,TMZ mono, ,Avastin mono, 
13381,133815,US,2L,1957,57,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,9,9,9,9,100,Lomustine mono, ,Avastin mono, 
13385,133851,US,1L,1959,56,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,0,0,100,Lomustine mono, ,999, 
13385,133852,US,1L,1975,40,Female,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,0,0,100,Lomustine mono, ,999, 
13385,133853,US,2L,1980,34,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,0,0,0,0,85,Lomustine mono, ,Avastin mono, 
13385,133854,US,2L,1959,55,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,0,0,0,100,Lomustine mono, ,Avastin mono, 
13385,133855,US,2L,1983,31,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,1,0,0,0,90,TMZ mono, ,Avastin mono, 
13393,133931,US,1L,1959,56,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,9,9,9,9,99,TMZ mono, ,999, 
13393,133932,US,1L,1935,80,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0, ,0,3,9,0,9,9,9,9,50,TMZ mono, ,999, 
13393,133933,US,2L,1962,51,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,bipolar,0,1,1,1,9,9,9,9,99,TMZ mono, ,Avastin mono, 
13393,133934,US,2L,1947,68,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,3,1,9,9,9,9,99,TMZ mono, ,Avastin mono, 
13393,133935,US,2L,1956,59,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,9,9,9,9,90,TMZ mono, ,Avastin + Irinotecan, 
13417,134171,US,1L,1940,75,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,9,9,9,9,90,TMZ mono, ,999, 
13417,134172,US,1L,1955,60,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,99,TMZ mono, ,999, 
13417,134173,US,2L,1945,70,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,9,9,9,9,9,75,TMZ mono, ,Avastin mono, 
13417,134174,US,2L,1939,76,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,9,9,9,9,9,99,TMZ mono, ,Avastin mono, 
13417,134175,US,2L,1958,57,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,50,TMZ mono, ,Avastin mono, 
13418,134181,US,1L,1948,67,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,9,9,9,9,999,Avastin mono, ,999, 
13418,134182,US,1L,1963,52,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0, ,0,1,9,0,9,9,9,9,999,Avastin mono, ,999, 
13418,134183,US,2L,1943,72,Female,Asian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0, ,0,1,1,0,9,9,9,9,90,Other,lomustine,Avastin mono, 
13418,134184,US,2L,1964,50,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,0,0,0,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13418,134185,US,2L,1955,60,Female,Other,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,0,9,9,9,9,95,TMZ mono, ,Other,cyberknife and temozolomide
13420,134201,US,1L,1951,68,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,1,4,9,9,9,9,9,9,95,TMZ mono, ,999, 
13420,134202,US,1L,1960,59,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,1,4,9,9,9,9,9,9,95,TMZ mono, ,999, 
13420,134203,US,2L,1955,64,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,1,4,0,9,9,9,9,9,95,TMZ mono, ,TMZ mono, 
13420,134204,US,2L,1953,66,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,1,4,0,9,9,9,9,9,95,TMZ mono, ,TMZ mono, 
13420,134205,US,2L,1939,80,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,1,4,0,9,9,9,9,9,85,TMZ mono, ,TMZ mono, 
13421,134211,US,1L,1937,78,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,0,0,0,0,90,TMZ mono, ,999, 
13421,134212,US,1L,1940,75,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,0,0,0,0,99,TMZ mono, ,999, 
13421,134213,US,2L,1941,74,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,1,0,0,0,0,0,80,TMZ mono, ,Avastin mono, 
13421,134214,US,2L,1938,77,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,0,0,0,0,999,Avastin mono, ,Avastin mono, 
13421,134215,US,2L,1937,78,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,0,0,0,0,0,999,TMZ mono, ,Avastin mono, 
13428,134281,US,1L,1955,57,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,3,9,9,9,9,9,9,999,Avastin mono, ,999, 
13428,134282,US,1L,1966,48,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,9,9,9,9,9,999,Avastin mono, ,999, 
13428,134283,US,2L,1933,82,Male,White/Caucasian,9,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,4,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13428,134284,US,2L,1944,71,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,3,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13428,134285,US,2L,1932,83,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,9,9,9,9,9,999,Avastin mono, ,Avastin + Lomustine, 
13430,134301,US,1L,1971,44,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,90,TMZ mono, ,999, 
13430,134302,US,1L,1942,73,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,9,9,9,9,9,999,Avastin mono, ,999, 
13430,134303,US,2L,1966,49,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,9,9,9,9,9,80,TMZ mono, ,Avastin mono, 
13430,134304,US,2L,1944,71,Female,White/Caucasian,9,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,9,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13430,134305,US,2L,1967,48,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13443,134431,US,1L,1960,49,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,1,1,0,1,80,Avastin mono, ,999, 
13443,134432,US,1L,1970,42,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0, ,0,2,9,1,1,1,1,1,75,Lomustine mono, ,999, 
13443,134433,US,2L,1960,55,Female,Spanish/Hispanic/Latino,0,0,Passive / not interested / unengaged,More focused on Survival,Medicaid,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0, ,0,2,0,0,1,0,0,1,50,Lomustine mono, ,Avastin + Irinotecan, 
13443,134434,US,2L,1955,59,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Exchange,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0, ,0,2,3,0,1,1,0,1,999,Avastin + Irinotecan, ,TMZ mono, 
13443,134435,US,2L,1972,41,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,HMO,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,3,2,0,1,1,1,0,999,Avastin + TMZ, ,Lomustine mono, 
13452,134521,US,1L,1968,47,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,1,0,0,1,75,Avastin mono, ,999, 
13452,134522,US,1L,1982,33,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0, ,0,1,9,0,9,0,0,9,80,Avastin + Irinotecan, ,999, 
13452,134523,US,2L,1965,50,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,3,0,9,0,1,9,90,Avastin + Irinotecan, ,Avastin + TMZ, 
13452,134524,US,2L,1956,59,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0, ,0,0,2,0,9,9,9,0,75,Avastin + Irinotecan, ,Avastin + TMZ, 
13452,134525,US,2L,1963,52,Female,Asian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,1,9,9,9,0,80,Avastin + Irinotecan, ,Avastin + TMZ, 
13455,134551,US,1L,1955,60,Female,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,0,0,0,0,90,TMZ mono, ,999, 
13455,134552,US,1L,1965,50,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,0,0,100,Lomustine mono, ,999, 
13455,134553,US,2L,1964,51,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,0,0,0,0,999,TMZ mono, ,Avastin mono, 
13455,134554,US,2L,1944,71,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,0,0,80,TMZ mono, ,Avastin mono, 
13455,134555,US,2L,1941,74,Female,Black/African,1,1,Active / knowledgeable / questioning,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,0,0,999,Avastin mono, ,Avastin mono, 
13461,134611,US,1L,1953,62,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0, ,0,1,9,9,9,9,9,9,80,TMZ mono, ,999, 
13461,134612,US,1L,1956,59,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,HMO,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0, ,0,1,9,9,9,9,9,9,90,TMZ mono, ,999, 
13461,134613,US,2L,1951,63,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Survival,Exchange,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0, ,0,1,1,9,9,9,9,9,90,TMZ mono, ,Avastin + Irinotecan, 
13461,134614,US,2L,1954,60,Male,Asian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0, ,0,1,1,9,9,9,9,9,85,TMZ mono, ,Avastin + Irinotecan, 
13461,134615,US,2L,1955,59,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0, ,0,1,1,9,9,9,9,9,90,TMZ mono, ,Avastin + Irinotecan, 
13462,134621,US,1L,1955,60,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,0,0,0,9,95,TMZ mono, ,999, 
13462,134622,US,1L,1975,40,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,0,0,1,0,99,TMZ mono, ,999, 
13462,134623,US,2L,1967,46,Male,Black/African,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,1,1,0,0,9,99,TMZ mono, ,TMZ mono, 
13462,134624,US,2L,1951,63,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Quality of Life,HMO,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,0,0,1,0,0,1,0,9,90,TMZ mono, ,Avastin mono, 
13462,134625,US,2L,1964,51,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,0,9,9,0,9,50,TMZ mono, ,Avastin + Lomustine, 
13463,134631,US,1L,1960,55,Female,Black/African,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,9,9,9,9,9,100,TMZ mono, ,999, 
13463,134632,US,1L,1972,43,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,9,9,9,100,TMZ mono, ,999, 
13463,134633,US,2L,1947,68,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,80,TMZ mono, ,Avastin + TMZ, 
13463,134634,US,2L,1952,63,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,70,TMZ mono, ,Avastin + TMZ, 
13463,134635,US,2L,1960,55,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,9,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,9,9,9,9,55,TMZ mono, ,Avastin + TMZ, 
13466,134661,US,1L,1961,54,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0, ,0,0,9,9,0,9,9,9,25,TMZ mono, ,999, 
13466,134662,US,1L,1954,61,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,9,0,9,9,9,20,TMZ mono, ,999, 
13466,134663,US,2L,1959,56,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,0,9,9,0,40,Lomustine mono, ,Avastin + TMZ, 
13466,134664,US,2L,1946,69,Male,Spanish/Hispanic/Latino,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0, ,0,1,2,1,1,9,9,0,25,TMZ mono, ,Lomustine mono, 
13466,134665,US,2L,1952,63,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,1,1,9,9,0,999,Avastin mono, ,Avastin + TMZ, 
13467,134671,US,1L,1934,81,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,0,0,0,0,0,999,Avastin mono, ,999, 
13467,134672,US,1L,1936,79,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,9,0,0,0,0,0,999,Avastin mono, ,999, 
13467,134673,US,2L,1933,82,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,1,1,0,0,0,0,0,999,Avastin mono, ,Avastin + Lomustine, 
13467,134674,US,2L,1937,78,Male,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,0,1,0,0,0,0,0,999,Avastin mono, ,Avastin + TMZ, 
13467,134675,US,2L,1936,79,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0, ,0,0,1,0,0,0,0,0,999,Avastin mono, ,Avastin + Irinotecan, 
13470,134701,US,1L,1949,65,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,1,9,9,9,999,Avastin mono, ,999, 
13470,134702,US,1L,1959,55,Female,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,1,9,0,1,999,Lomustine mono, ,999, 
13470,134703,US,2L,1951,63,Male,Black/African,0,0,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0, ,0,1,2,1,1,9,0,1,999,Lomustine mono, ,Avastin mono, 
13470,134704,US,2L,1952,62,Female,Spanish/Hispanic/Latino,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0, ,0,0,1,1,1,9,0,1,999,Avastin mono, ,Lomustine mono, 
13470,134705,US,2L,1948,66,Female,Asian,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,1,1,9,0,1,999,Avastin mono, ,Lomustine mono, 
13471,134711,US,1L,1950,65,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,9,9,0,0,9,9,99,TMZ mono, ,999, 
13471,134712,US,1L,1952,63,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,0,9,9,1,0,9,9,99,TMZ mono, ,999, 
13471,134713,US,2L,1958,56,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Survival,PPO,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,0,0,0,0,0,95,Lomustine mono, ,Avastin + Irinotecan, 
13471,134714,US,2L,1960,54,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,1,0,0,0,1,99,TMZ mono, ,Avastin + Irinotecan, 
13471,134715,US,2L,1948,67,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0, ,0,1,1,0,9,9,9,9,999,Avastin + TMZ, ,Avastin + Irinotecan, 
13472,134721,US,1L,1989,30,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,1,4,9,9,9,9,9,9,98,TMZ mono, ,999, 
13472,134722,US,1L,1984,35,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,1,4,9,9,9,9,9,9,89,TMZ mono, ,999, 
13472,134723,US,2L,1984,35,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,1,4,0,9,9,9,9,9,87,TMZ mono, ,TMZ mono, 
13472,134724,US,2L,1978,41,Female,Black/African,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,1,4,0,9,9,9,9,9,97,TMZ mono, ,TMZ mono, 
13472,134725,US,2L,1982,37,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,1,4,0,9,9,9,9,9,999,TMZ mono, ,TMZ mono, 
13473,134731,US,1L,1958,57,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,9,1,0,9,90,TMZ mono, ,999, 
13473,134732,US,1L,1964,51,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,9,9,0,9,75,TMZ mono, ,999, 
13473,134733,US,2L,1966,48,Male,Asian,1,1,Average level of engagement with the disease,More focused on Survival,HMO,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,9,1,0,9,85,Lomustine mono, ,Avastin mono, 
13473,134734,US,2L,1947,67,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,9,9,0,9,85,TMZ mono, ,Avastin mono, 
13473,134735,US,2L,1953,60,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,0,9,1,0,9,90,Lomustine mono, ,Avastin mono, 
13474,134741,US,1L,1969,46,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,0,2,9,9,1,0,0,0,999,Avastin mono, ,999, 
13474,134742,US,1L,1968,47,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,1,1,0,0,43,Lomustine mono, ,999, 
13474,134743,US,2L,1962,53,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,1,0,1,9,0,9,32,Avastin mono, ,Avastin mono, 
13474,134744,US,2L,1967,48,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,2,0,0,0,0,0,999,Avastin mono, ,Avastin + Irinotecan, 
13474,134745,US,2L,1961,54,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,0,1,2,1,0,0,1,1,43,Avastin mono, ,Lomustine mono, 
13477,134771,US,1L,1956,59,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,Medicaid,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,1,9,9,9,9,95,TMZ mono, ,999, 
13477,134772,US,1L,1951,64,Female,Asian,1,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,9,9,9,9,9,9,999,Avastin mono, ,999, 
13477,134773,US,2L,1972,43,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,obese,0,1,1,1,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13477,134774,US,2L,1981,33,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,0,0,9,9,9,9,99,TMZ mono, ,Avastin mono, 
13477,134775,US,2L,1947,67,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0, ,0,1,1,1,9,9,9,9,95,TMZ mono, ,Avastin mono, 
13480,134801,US,1L,1965,49,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0, ,0,2,9,0,1,0,1,1,56,Lomustine mono, ,999, 
13480,134802,US,1L,1971,43,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0, ,0,2,9,1,1,1,0,0,56,Avastin mono, ,999, 
13480,134803,US,2L,1964,50,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,1,0,0,0,54,Lomustine mono, ,Lomustine mono, 
13480,134804,US,2L,1965,49,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,2,1,1,1,0,1,64,Avastin mono, ,Avastin + Irinotecan, 
13480,134805,US,2L,1972,42,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,2,0,1,1,9,0,46,Avastin + Irinotecan, ,Lomustine mono, 
13483,134831,US,1L,1970,44,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,1,0,9,9,35,Avastin + Irinotecan, ,999, 
13483,134832,US,1L,1968,46,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,1,1,0,0,34,Avastin + Irinotecan, ,999, 
13483,134833,US,2L,1972,42,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,1,1,1,1,55,Lomustine mono, ,Avastin + Irinotecan, 
13483,134834,US,2L,1970,44,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0, ,0,1,2,0,1,1,0,0,46,TMZ mono, ,Avastin mono, 
13483,134835,US,2L,1973,41,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,1,1,1,1,1,1,56,TMZ mono, ,Avastin mono, 
13484,134841,US,1L,1971,44,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,9,1,9,9,0,34,Avastin mono, ,999, 
13484,134842,US,1L,1968,47,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,9,0,0,9,9,37,Avastin + Irinotecan, ,999, 
13484,134843,US,2L,1972,43,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,0,0,31,Avastin mono, ,Avastin + Lomustine, 
13484,134844,US,2L,1962,53,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,1,1,0,1,43,TMZ mono, ,Avastin mono, 
13484,134845,US,2L,1970,45,Female,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Quality of Life,Exchange,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,0,0,0,0,21,Avastin mono, ,Avastin + Lomustine, 
13486,134861,US,1L,1957,58,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,9,9,9,9,9,90,TMZ mono, ,999, 
13486,134862,US,1L,1947,68,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0, ,0,1,9,9,9,9,9,9,100,TMZ mono, ,999, 
13486,134863,US,2L,1943,72,Female,Black/African,1,0,Passive / not interested / unengaged,More focused on Quality of Life,HMO,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0, ,0,1,2,9,9,9,9,9,90,TMZ mono, ,Avastin mono, 
13486,134864,US,2L,1963,52,Female,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0, ,0,1,1,9,9,9,9,9,100,TMZ mono, ,Avastin mono, 
13486,134865,US,2L,1953,61,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0, ,0,1,1,9,9,9,9,9,100,TMZ mono, ,Avastin + TMZ, 
13489,134891,US,1L,1970,44,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,2,9,1,1,1,1,1,43,Avastin mono, ,999, 
13489,134892,US,1L,1970,44,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,1,1,1,0,1,46,Avastin + Lomustine, ,999, 
13489,134893,US,2L,1958,56,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,0,0,9,0,23,Lomustine mono, ,Avastin mono, 
13489,134894,US,2L,1959,56,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,0,0,0,37,Lomustine mono, ,Avastin mono, 
13489,134895,US,2L,1966,49,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,0,1,0,0,0,0,0,37,Lomustine mono, ,Avastin + Irinotecan, 
13494,134941,US,1L,1958,57,Male,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,1,0,0,23,Avastin mono, ,999, 
13494,134942,US,1L,1963,52,Female,Black/African,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,0,0,0,0,34,Avastin mono, ,999, 
13494,134943,US,2L,1965,50,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,0,9,43,Lomustine mono, ,Avastin + Irinotecan, 
13494,134944,US,2L,1963,52,Female,Spanish/Hispanic/Latino,0,0,Active / knowledgeable / questioning,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,1,1,1,0,47,Avastin mono, ,Avastin + Irinotecan, 
13494,134945,US,2L,1956,59,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,0,0,0,39,Avastin + Irinotecan, ,Lomustine mono, 
13496,134961,US,1L,1980,34,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,1,1,1,34,Avastin mono, ,999, 
13496,134962,US,1L,1974,40,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,1,1,1,1,1,54,Avastin + Irinotecan, ,999, 
13496,134963,US,2L,1971,43,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,1,1,1,1,56,Lomustine mono, ,Avastin mono, 
13496,134964,US,2L,1969,45,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,1,1,1,1,1,43,Avastin mono, ,Avastin + Irinotecan, 
13496,134965,US,2L,1965,49,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,1,1,1,43,TMZ mono, ,Avastin + Irinotecan, 
13499,134991,US,1L,1962,53,Female,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,0,42,Avastin mono, ,999, 
13499,134992,US,1L,1957,58,Female,Spanish/Hispanic/Latino,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,9,43,TMZ mono, ,999, 
13499,134993,US,2L,1952,63,Male,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,0,9,0,42,Avastin mono, ,Avastin mono, 
13499,134994,US,2L,1963,52,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,3,1,0,1,1,0,0,43,Avastin + Irinotecan, ,Lomustine mono, 
13499,134995,US,2L,1955,60,Male,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,1,0,0,0,36,Avastin + Irinotecan, ,Avastin + TMZ, 
13500,135001,US,1L,1968,51,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,1,4,9,9,9,9,9,9,55,TMZ mono, ,999, 
13500,135002,US,1L,1964,55,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,1,4,9,9,9,9,9,9,54,TMZ mono, ,999, 
13500,135003,US,2L,1968,51,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,1,4,0,9,9,9,9,9,46,TMZ mono, ,TMZ mono, 
13500,135004,US,2L,1968,51,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,1,4,0,9,9,9,9,9,55,TMZ mono, ,TMZ mono, 
13500,135005,US,2L,1965,54,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0, ,1,4,0,9,9,9,9,9,56,TMZ mono, ,TMZ mono, 
13501,135011,US,1L,1957,58,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,9,43,Avastin mono, ,999, 
13501,135012,US,1L,1970,45,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,0,0,0,14,Avastin mono, ,999, 
13501,135013,US,2L,1956,59,Female,Black/African,0,0,Average level of engagement with the disease,More focused on Quality of Life,Medicare,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,0,1,1,34,Avastin + Irinotecan, ,Avastin + Lomustine, 
13501,135014,US,2L,1972,43,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,9,0,56,Avastin mono, ,Lomustine mono, 
13501,135015,US,2L,1954,61,Male,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0, ,0,1,3,0,0,9,0,0,47,Lomustine mono, ,Avastin + Irinotecan, 
13503,135031,US,1L,1968,46,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,1,1,1,1,56,Lomustine mono, ,999, 
13503,135032,US,1L,1960,54,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,1,1,1,1,1,56,Lomustine mono, ,999, 
13503,135033,US,2L,1966,48,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,1,1,1,1,1,56,Avastin mono, ,Avastin mono, 
13503,135034,US,2L,1967,47,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,1,1,1,1,56,Lomustine mono, ,Avastin mono, 
13503,135035,US,2L,1970,44,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,1,1,1,1,44,TMZ mono, ,Avastin + Irinotecan, 
13505,135051,US,1L,1940,75,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0, ,0,1,9,1,9,9,9,9,50,TMZ mono, ,999, 
13505,135052,US,1L,1952,63,Female,Spanish/Hispanic/Latino,1,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,9,0,9,9,9,9,70,Lomustine mono, ,999, 
13505,135053,US,2L,1955,60,Female,Asian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0, ,0,1,1,1,9,9,9,9,999,TMZ mono, ,Avastin mono, 
13505,135054,US,2L,1965,48,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,1,1,9,9,9,9,90,TMZ mono, ,Avastin + TMZ, 
13505,135055,US,2L,1962,52,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0, ,0,1,1,0,9,9,9,9,60,Lomustine mono, ,Avastin mono, 
13506,135061,US,1L,1967,48,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,0,0,0,9,0,37,Avastin mono, ,999, 
13506,135062,US,1L,1970,45,Female,Black/African,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Uninsured,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,9,32,Avastin mono, ,999, 
13506,135063,US,2L,1963,52,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,0,0,0,9,9,38,Avastin mono, ,Avastin + Lomustine, 
13506,135064,US,2L,1954,61,Male,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,0,0,9,9,36,Lomustine mono, ,Avastin + Irinotecan, 
13506,135065,US,2L,1953,62,Male,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,0,0,9,9,31,Lomustine mono, ,Avastin + Irinotecan, 
13507,135071,US,1L,1965,49,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,0,1,1,1,1,56,Avastin mono, ,999, 
13507,135072,US,1L,1971,43,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,1,1,1,43,Avastin mono, ,999, 
13507,135073,US,2L,1964,50,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,1,1,1,1,43,TMZ mono, ,Avastin mono, 
13507,135074,US,2L,1972,42,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,1,1,1,46,Lomustine mono, ,Avastin + Irinotecan, 
13507,135075,US,2L,1973,41,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,1,1,1,1,1,54,Avastin mono, ,Avastin + Irinotecan, 
13508,135081,US,1L,1963,52,Male,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,9,37,Avastin mono, ,999, 
13508,135082,US,1L,1952,63,Male,Black/African,1,0,Passive / not interested / unengaged,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,0,42,Avastin mono, ,999, 
13508,135083,US,2L,1952,62,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,0,0,0,34,Lomustine mono, ,Avastin + Lomustine, 
13508,135084,US,2L,1956,58,Female,Spanish/Hispanic/Latino,0,0,Average level of engagement with the disease,More focused on Survival,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,1,0,0,0,38,Avastin + Irinotecan, ,Lomustine mono, 
13508,135085,US,2L,1962,53,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,0,9,0,46,Avastin mono, ,Avastin + Irinotecan, 
13510,135101,US,1L,1963,51,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,1,1,1,34,Avastin + Irinotecan, ,999, 
13510,135102,US,1L,1960,54,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,1,1,1,1,1,33,Lomustine mono, ,999, 
13510,135103,US,2L,1963,51,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,1,1,1,0,1,32,Avastin mono, ,Avastin + Lomustine, 
13510,135104,US,2L,1965,49,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,1,0,1,1,1,1,43,Lomustine mono, ,Avastin mono, 
13510,135105,US,2L,1966,48,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,1,1,0,1,54,TMZ mono, ,Avastin mono, 
13511,135111,US,1L,1952,63,Female,Spanish/Hispanic/Latino,1,0,Passive / not interested / unengaged,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,0,0,0,32,Lomustine mono, ,999, 
13511,135112,US,1L,1972,43,Female,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,9,42,Avastin mono, ,999, 
13511,135113,US,2L,1954,61,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,9,9,46,Avastin mono, ,Avastin + Irinotecan, 
13511,135114,US,2L,1961,54,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,9,9,43,Avastin mono, ,Avastin + Lomustine, 
13511,135115,US,2L,1960,55,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,0,0,9,0,38,Avastin mono, ,Avastin + Lomustine, 
13512,135121,US,1L,1967,47,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,1,1,1,1,43,Lomustine mono, ,999, 
13512,135122,US,1L,1963,51,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,1,1,1,46,Avastin + Irinotecan, ,999, 
13512,135123,US,2L,1967,47,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,1,1,1,55,Lomustine mono, ,Avastin + Irinotecan, 
13512,135124,US,2L,1958,56,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,1,1,1,1,1,54,Lomustine mono, ,Avastin + Lomustine, 
13512,135125,US,2L,1964,50,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,0,1,1,1,1,54,Avastin mono, ,Avastin + Irinotecan, 
13515,135151,US,1L,1963,52,Female,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,9,9,9,37,Avastin mono, ,999, 
13515,135152,US,1L,1964,51,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,0,0,9,9,47,Lomustine mono, ,999, 
13515,135153,US,2L,1969,45,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,9,9,38,Avastin mono, ,Avastin + Lomustine, 
13515,135154,US,2L,1967,47,Male,Spanish/Hispanic/Latino,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,1,0,0,0,46,Avastin mono, ,Avastin + Irinotecan, 
13515,135155,US,2L,1964,50,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,0,0,0,0,0,1,49,Avastin + Irinotecan, ,Lomustine mono, 
13516,135161,US,1L,1971,43,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,1,1,1,32,Avastin mono, ,999, 
13516,135162,US,1L,1969,45,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,1,1,1,43,Lomustine mono, ,999, 
13516,135163,US,2L,1960,54,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,1,1,1,1,54,Lomustine mono, ,Avastin mono, 
13516,135164,US,2L,1960,54,Male,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,1,1,1,1,46,Lomustine mono, ,Avastin mono, 
13516,135165,US,2L,1964,50,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,1,1,1,1,1,44,Lomustine mono, ,Avastin + Lomustine, 
13517,135171,US,1L,1967,48,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,0,0,9,9,34,Avastin mono, ,999, 
13517,135172,US,1L,1967,46,Female,Spanish/Hispanic/Latino,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,0,9,9,9,31,Avastin mono, ,999, 
13517,135173,US,2L,1962,51,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,0,0,9,9,57,Avastin mono, ,Avastin + Lomustine, 
13517,135174,US,2L,1967,48,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,0,1,2,0,0,1,9,0,42,Avastin + Irinotecan, ,Lomustine mono, 
13517,135175,US,2L,1970,45,Male,Black/African,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,9,9,9,47,Avastin + Irinotecan, ,Lomustine mono, 
13521,135211,US,1L,1970,44,Male,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,1,1,1,45,Avastin + Irinotecan, ,999, 
13521,135212,US,1L,1964,50,Female,White/Caucasian,0,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,1,1,1,1,46,Avastin mono, ,999, 
13521,135213,US,2L,1964,50,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,1,1,1,1,1,56,TMZ mono, ,Avastin mono, 
13521,135214,US,2L,1964,50,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,1,1,1,46,Lomustine mono, ,Avastin + Irinotecan, 
13521,135215,US,2L,1967,47,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,1,1,1,1,1,1,56,Lomustine mono, ,Avastin mono, 
13525,135251,US,1L,1964,51,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,9,0,1,9,0,0,34,Lomustine mono, ,999, 
13525,135252,US,1L,1963,52,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,0,0,9,9,45,Lomustine mono, ,999, 
13525,135253,US,2L,1972,42,Female,White/Caucasian,0,1,Average level of engagement with the disease,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,1,0,9,9,32,Avastin mono, ,Avastin + Lomustine, 
13525,135254,US,2L,1970,43,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0, ,0,1,2,9,0,0,9,9,67,Avastin mono, ,Avastin + Lomustine, 
13525,135255,US,2L,1970,44,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicaid,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0, ,0,0,2,9,9,0,9,9,44,Avastin mono, ,Avastin + Irinotecan, 
13526,135261,US,1L,1967,47,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,1,1,1,45,Avastin + Irinotecan, ,999, 
13526,135262,US,1L,1964,50,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,1,1,1,63,TMZ mono, ,999, 
13526,135263,US,2L,1963,51,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,2,2,1,1,1,1,1,54,Avastin mono, ,Avastin + Irinotecan, 
13526,135264,US,2L,1966,48,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,1,1,1,1,44,Avastin mono, ,Avastin + Irinotecan, 
13526,135265,US,2L,1967,47,Male,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,0,1,1,1,1,46,Avastin mono, ,Avastin + Irinotecan, 
13529,135291,US,1L,1966,48,Female,White/Caucasian,0,0,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,1,1,1,56,Avastin mono, ,999, 
13529,135292,US,1L,1963,51,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,1,1,1,1,1,34,Avastin + Irinotecan, ,999, 
13529,135293,US,2L,1970,44,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,1,1,1,1,1,56,Lomustine mono, ,Avastin + Lomustine, 
13529,135294,US,2L,1971,43,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,1,1,1,1,43,Lomustine mono, ,Avastin + Irinotecan, 
13529,135295,US,2L,1970,44,Male,Black/African,1,1,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,1,1,1,1,1,33,Lomustine mono, ,Avastin mono, 
13532,135321,US,1L,1974,45,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Uninsured,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0, ,1,4,9,9,9,9,9,9,32,TMZ mono, ,999, 
13532,135322,US,1L,1975,44,Female,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Quality of Life,Medicaid,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0, ,1,4,9,9,9,9,9,9,43,TMZ mono, ,999, 
13532,135323,US,2L,1958,61,Male,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Quality of Life,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0, ,1,4,0,9,9,9,9,9,32,TMZ mono, ,TMZ mono, 
13532,135324,US,2L,1952,67,Female,Spanish/Hispanic/Latino,0,0,Passive / not interested / unengaged,More focused on Quality of Life,Exchange,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0, ,1,4,0,9,9,9,9,9,29,TMZ mono, ,TMZ mono, 
13532,135325,US,2L,1961,58,Male,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0, ,1,4,0,9,9,9,9,9,36,TMZ mono, ,TMZ mono, 
13533,135331,US,1L,1970,44,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,9,0,1,1,1,1,46,Avastin + Lomustine, ,999, 
13533,135332,US,1L,1969,45,Male,White/Caucasian,0,0,Average level of engagement with the disease,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,0,1,1,1,1,44,Avastin + Irinotecan, ,999, 
13533,135333,US,2L,1956,58,Male,White/Caucasian,1,0,Active / knowledgeable / questioning,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,0,1,1,1,1,46,TMZ mono, ,Avastin + Irinotecan, 
13533,135334,US,2L,1966,48,Male,White/Caucasian,1,0,Average level of engagement with the disease,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,2,1,1,1,1,1,33,Avastin mono, ,Avastin + Irinotecan, 
13533,135335,US,2L,1967,47,Male,White/Caucasian,1,1,Active / knowledgeable / questioning,More focused on Survival,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,3,0,1,1,1,1,46,Lomustine mono, ,Avastin + Irinotecan, 
13536,135361,US,1L,1965,49,Female,White/Caucasian,1,0,Passive / not interested / unengaged,More focused on Quality of Life,HMO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,9,0,9,9,46,Avastin mono, ,999, 
13536,135362,US,1L,1971,43,Female,White/Caucasian,0,0,Passive / not interested / unengaged,More focused on Quality of Life,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,9,9,0,1,1,1,58,Lomustine mono, ,999, 
13536,135363,US,2L,1971,43,Male,White/Caucasian,1,1,Average level of engagement with the disease,More focused on Survival,Medicare,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,0,0,0,0,47,Lomustine mono, ,Avastin + Irinotecan, 
13536,135364,US,2L,1973,41,Female,Spanish/Hispanic/Latino,1,0,Passive / not interested / unengaged,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,1,2,9,1,0,9,9,47,Lomustine mono, ,Avastin + Lomustine, 
13536,135365,US,2L,1964,50,Male,Spanish/Hispanic/Latino,1,0,Passive / not interested / unengaged,More focused on Survival,PPO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0, ,1,0,1,0,1,0,0,0,46,Lomustine mono, ,Avastin + Irinotecan, 
